First-line lenvatinib plus pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.

被引：0

作者：

Lee, Chung-Han

Gurney, Howard

Atduev, Vagif

Suarez, Cristina

Duran, Miguel A. Climent

Pook, David William

Tomczak, Piotr

Barthelemy, Philippe

Lee, Jae-Lyun

Nalbandian, Taron

Stus, Viktor

Ferguson, Thomas

Wiechno, Pawel

Gokmen, Erhan

Lacombe, Louis

Gedye, Craig

Burgents, Joseph

Sharma, Manish

Peng, Xiang

Albiges, Laurence

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Macquarie Univ, Sydney, NSW, Australia

[3] Fed Med Biol Agcy, Volga Dist Med Ctr, Nizhnii Novgorod, Russia

[4] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[5] Inst Valenciano Oncol, Valencia, Spain

[6] Monash Hlth, Melbourne, Vic, Australia

[7] Poznan Univ Med Sci, Poznan, Poland

[8] Inst Cancerol Strasbourg Europe, Strasbourg, France

[9] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[10] Reg Canc Ctr, Kharkiv, Ukraine

[11] Dnipro State Med Univ, Dnipro, Ukraine

[12] Fiona Stanley Hosp, Perth, WA, Australia

[13] Inst Marii Sklodowskiej Curie, Oncol Ctr, Warsaw, Poland

[14] Ege Univ, Fac Med, Izmir, Turkiye

[15] CHU Quebec, Ctr Rech, Quebec City, PQ, Canada

[16] Univ Newcastle, Callaghan, NSW, Australia

[17] Merck & Co Inc, Rahway, NJ 07065 USA

[18] Gustave Roussy, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4518

引用

页数：1

共 50 条

[21] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
Wang, Ye
Wang, Hao
Yi, Manman
Han, Zhou
Li, Li
FRONTIERS IN ONCOLOGY, 2022, 12
[22] A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
Hutson, Thomas E.
Michaelson, M. Dror
Kuzel, Timothy M.
Agarwal, Neeraj
Molina, Ana M.
Hsieh, James J.
Vaishampayan, Ulka N.
Xie, Ran
Bapat, Urmi
Ye, Weifei
Jain, Rohit K.
Fishman, Mayer N.
EUROPEAN UROLOGY, 2021, 80 (02) : 162 - 170
[23] Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
McDermott, David F.
Lee, Jae-Lyun
Ziobro, Marek
Suarez, Cristina
Langiewicz, Przemyslaw
Matveev, Vsevolod Borisovich
Wiechno, Pawel
Gafanov, Rustem Airatovich
Tomczak, Piotr
Pouliot, Frederic
Donskov, Frede
Alekseev, Boris Yakovlevich
Shin, Sang Joon
Bjarnason, Georg A.
Castellano, Daniel
Silverman, Rachel Kloss
Perini, Rodolfo F.
Schloss, Charles
Atkins, Michael B.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (09)
[24] Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non-clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B
Lee, J-L.
McDermott, D. F.
Ziobro, M.
Suarez, C.
Langiewicz, P.
Matveev, V. B.
Wiechno, P.
Gafanov, R.
Tomczak, P.
Pouliot, F.
Donskov, F.
Alekseev, B. Y.
Shin, S. J.
Bjarnason, G. A.
Castellano, D.
Liu, H.
Burgents, J.
Rodriguez-Lopez, K.
Atkins, M. B.
ANNALS OF ONCOLOGY, 2021, 32 : S687 - S687
[25] Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
McDermott, David F.
Lee, Jae-Lyun
Szczylik, Cezary
Donskov, Frede
Malik, Jahangeer
Alekseev, Boris Yakovlevich
Larkin, James M. G.
Matveev, Vsevolod Borisovich
Gafanov, Rustem Airatovich
Tomczak, Piotr
Tykodi, Scott S.
Geertsen, Poul F.
Wiechno, Pawel J.
Shin, Sang Joon
Pouliot, Frederic
Gordoa, Teresa Alonso
Li, Wenting
Perini, Rodolfo F.
Schloss, Charles
Atkins, Michael B.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[26] First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study
Bersanelli, M.
Maines, F.
Facchini, G.
Gelsomino, F.
Zustovich, F.
Santoni, M.
Verri, E.
De Giorgi, U.
Masini, C.
Morelli, F.
Vitale, M. G.
Sava, T.
Prati, G.
Librici, C.
Fraccon, A. P.
Fornarini, G.
Maruzzo, M.
Leonardi, F.
Caffo, O.
Buti, S.
ANNALS OF ONCOLOGY, 2016, 27
[27] Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma
Zheng, Huanrui
Zhou, Jin
Tong, Yao
Zhang, Jinhua
CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
[28] First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study
Bersanelli, M.
Maines, F.
Facchini, G.
Gelsomino, F.
Zustovich, F.
Santoni, M.
Verri, E.
De Giorgi, U.
Masini, C.
Morelli, F.
Vitale, M. G.
Sava, T.
Prati, G.
Librici, C.
Fraccon, A. P.
Fornarini, G.
Maruzzo, M.
Leonardi, F.
Caffo, O.
Buti, S.
ANNALS OF ONCOLOGY, 2016, 27
[29] KEYNOTE-426 Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma
Bedke, J.
Stuehler, V.
UROLOGE, 2020, 59 (07): : 841 - 842
[30] Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146
Lee, Chung-Han
Shah, Amishi Yogesh
Rao, Arpit
Taylor, Matthew H.
Di Simone, Christopher
Hsieh, James J.
Pinto, Alvaro
Sarrio, Regina Girones
Cohn, Allen Lee
Bilen, Mehmet Asim
Ribe, Sara Gunnestad
Tennoe, Oyvind Krohn
Richards, Donald
Sweis, Randy F.
Courtright, Jay
Heinrich, Daniel
Perini, Rodolfo
Kubiak, Peter
Bock, Daena
Okpara, Chinyere E.
Motzer, Robert J.
EUROPEAN UROLOGY, 2024, 86 (05) : 470 - 473

← 1 2 3 4 5 →